Thomas Deimel
Overview
Explore the profile of Thomas Deimel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
90
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tobudic S, Simader E, Deimel T, Straub J, Kartnig F, Heinz L, et al.
Front Med (Lausanne)
. 2023 Feb;
10:1049157.
PMID: 36844197
Objectives: This study aimed to assess the duration of humoral responses after two doses of SARS-CoV-2 mRNA vaccines in patients with inflammatory joint diseases and IBD and booster vaccination compared...
2.
Mrak D, Kartnig F, Sieghart D, Simader E, Radner H, Mandl P, et al.
J Autoimmun
. 2023 Jan;
135:102981.
PMID: 36706534
Background: A 3 COVID-19 vaccination is currently recommended for patients under immunosuppression. However, a fast decline of antibodies against the SARS-CoV-2 receptor-binding domain (RBD) of the spike protein has been...
3.
Gessl I, Hana C, Deimel T, Durechova M, Hucke M, Konzett V, et al.
Ann Rheum Dis
. 2022 Oct;
82(3):344-350.
PMID: 36261248
Objective: The aim of this study was to assess the predictive value of tenderness in the absence of swelling with consideration of other potential risk factors for subsequent radiographic progression...
4.
Goschl L, Mrak D, Grabmeier-Pfistershammer K, Stiasny K, Haslacher H, Schneider L, et al.
Front Immunol
. 2022 Oct;
13:974987.
PMID: 36189225
Background: Patients with inborn errors of immunity (IEI) are at increased risk for severe courses of SARS-CoV-2 infection. COVID-19 vaccination provides effective protection in healthy individuals. However, it remains unclear...
5.
Kartnig F, Mrak D, Simader E, Tobudic S, Radner H, Mandl P, et al.
Ann Rheum Dis
. 2022 Sep;
82(2):292-300.
PMID: 36109141
Objectives: A third COVID-19 vaccination is recommended for immunosuppressed patients. However, data on immunogenicity and safety of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases (IMIDs) are sparse...
6.
Mrak D, Sieghart D, Simader E, Tobudic S, Radner H, Mandl P, et al.
Nat Commun
. 2022 Sep;
13(1):5362.
PMID: 36097029
Impaired response to COVID-19 vaccination is of particular concern in immunosuppressed patients. To determine the best vaccination strategy for this vulnerable group we performed a single center, 1:1 randomized blinded...
7.
Mrak D, Simader E, Sieghart D, Mandl P, Radner H, Perkmann T, et al.
Ann Rheum Dis
. 2022 Aug;
81(12):1750-1756.
PMID: 35977809
Objectives: Patients under rituximab therapy are at high risk for a severe COVID-19 disease course. Humoral immune responses to SARS-CoV-2 vaccination are vastly diminished in B-cell-depleted patients, even after a...
8.
Gessl I, Popescu M, Schimpl V, Supp G, Deimel T, Durechova M, et al.
Ann Rheum Dis
. 2021 Jan;
80(7):884-890.
PMID: 33436384
Objectives: To determine whether clinical tenderness can be considered a sign of inflammatory joint activity in patients with rheumatoid arthritis (RA), osteoarthritis (OA) or psoriatic arthritis (PsA) and to assess...